The Truth About Prostate Biopsy

Prostate biopsy remains the only definitive way to diagnose prostate cancer, but the procedure carries real trade-offs that are often glossed over in a brief urologist visit. The path from an elevated PSA blood test to a tissue sample involves decisions about imaging, biopsy technique, infection prevention, and pain control, each of which meaningfully affects what you experience and what the results can tell you. The science has shifted considerably in the last decade, and many men are still offered a version of the procedure that lags behind current evidence.

The PSA Problem That Starts the Whole Process

Most prostate biopsies happen because of an elevated prostate-specific antigen level on a blood test. What many men are not told clearly is how often that elevated number turns out to be a false alarm. In a cohort study of over 1,600 patients, the false-positive PSA rate was about 47%, while the positive predictive value of the test was only around 13%. That means roughly seven out of eight men with a “positive” PSA result did not actually have prostate cancer.¹ PSA can be elevated by infections, an enlarged prostate, recent ejaculation, vigorous exercise, and other benign causes. The test is good at ruling cancer out (a negative result was correct more than 99% of the time in that same study), but it is poor at confirming cancer is present.

This matters because it means a large number of biopsies are performed on men who do not have cancer. Some of those men experience pain, bleeding, infection, or anxiety from a procedure that, in retrospect, they did not need. The question is not whether PSA screening has value but whether every elevated PSA should lead straight to a needle.

Pre-Biopsy MRI Can Spare You a Needle

One of the biggest shifts in prostate cancer diagnosis over the past decade is the use of multiparametric MRI before biopsy. The landmark PROMIS trial found that using MRI as a triage step could allow roughly a quarter of men to avoid a primary biopsy altogether, while also diagnosing 5% fewer clinically insignificant cancers and detecting up to 18% more of the cancers that actually matter.² In an Australian cohort, up to half of biopsies that came back negative or showed only low-grade disease had MRI scores suggesting no significant abnormality, reinforcing the idea that those biopsies could have been avoided.³

There is a catch, though. A separate prospective study found that while pre-biopsy MRI improved detection of significant cancers in men who had never been biopsied before, it did not eliminate the need for systematic biopsy entirely.⁴ MRI can miss some cancers, particularly small ones or those in tricky locations. The current consensus in most major guidelines is that MRI should come before a first biopsy, and that if the MRI looks clean, a careful conversation about whether to proceed is appropriate. But if the MRI flags a suspicious area, biopsy is still the next step.

How the Biopsy Is Done Matters More Than You Think

There are two main ways to get a needle into the prostate: through the rectum (transrectal, or TR) and through the perineum, the skin between the scrotum and anus (transperineal, or TP). For decades, the transrectal route dominated because it was simpler to perform with standard ultrasound. But the needle passes through the rectal wall, which is teeming with bacteria, and that creates an inherent infection risk.

The transperineal approach avoids the rectal wall entirely. A meta-analysis of studies comparing the two routes found that the transperineal approach reduced the odds of hospitalization for infectious complications by 77% and lowered the rate of post-procedure fever as well.⁵ A single-center study found infection rates of about 1.2% for perineal biopsies compared with 4.1% for rectal biopsies, and all four patients who needed hospital admission for bacteremia had undergone the transrectal route.⁶

Beyond infection, the transperineal approach also appears better at reaching the anterior part of the prostate, an area that the rectal route notoriously under-samples. One comparison found that transperineal biopsy detected over 93% of anterior-zone cancers compared with just 25% for the transrectal method.⁷ Despite all this, adoption of the transperineal technique varies enormously. An analysis of American Urological Association census data found up to a nearly seven-fold difference across U.S. states in how often the transperineal route was used, with younger urologists and those with oncology fellowship training more likely to offer it.

Targeted Versus Systematic Biopsy

A “systematic” biopsy takes 10 to 12 cores from pre-set locations throughout the prostate, essentially sampling blind. A “targeted” or fusion biopsy overlays pre-biopsy MRI images onto a live ultrasound feed, allowing the urologist to aim needles directly at suspicious spots. Both techniques catch cancers the other misses, which is why many centers now do both at the same sitting.

In one study of over 500 patients, systematic biopsy alone found cancer in about 39% of cases, while MRI/ultrasound fusion biopsy alone found it in about 43%. Among all the positive cases, roughly one in four was detected only by fusion-guided cores, while about one in six was detected only by systematic cores.⁸ Another study found a roughly 5-to-6 percentage point advantage for fusion biopsy in detecting clinically significant cancer, though even there, about 12% of significant cancers were caught only by the systematic approach.⁹

The practical takeaway is that neither approach alone is perfect. If your urologist offers only systematic biopsy without MRI guidance, you are likely missing a meaningful number of significant cancers and potentially over-detecting insignificant ones. And if the plan is MRI-targeted cores only, some cancers in areas that looked fine on imaging may slip through. Combining both is the current best practice for a first biopsy.

What the Biopsy Gets Wrong About Grade

Even when a biopsy finds cancer, the grade it assigns may not be the full story. The Gleason score assigned from biopsy cores is based on tiny slivers of tissue, while the actual tumor in the whole prostate can look quite different. Upgrading, where the cancer turns out to be more aggressive than the biopsy suggested, happens frequently. One review noted that this occurs in up to a third of patients who go on to surgery.¹⁰

The rates can be even more striking for low-grade findings. In one series, among men whose biopsy showed a Gleason score of 6, over 70% were upgraded when the entire prostate was examined after surgery. Even among men who met the criteria for active surveillance, close to 58% turned out to have higher-grade disease.¹¹ Another study confirmed a significant average increase in Gleason score from biopsy to surgical specimen, with upgrading in about 55% of cases, particularly when the initial score was low or fewer cores were taken.¹²

This does not mean the biopsy is useless for grading. It means that a low biopsy score should not automatically be equated with harmlessness. It is one of the reasons men on active surveillance need ongoing monitoring rather than a single “all clear.”

Pain, Bleeding, and Sexual Side Effects

Many men are told a prostate biopsy is “uncomfortable but tolerable.” That is often true, but the range of experiences is wider than that phrase suggests. A systematic review and network meta-analysis found that a periprostatic nerve block, where local anesthetic is injected around the prostate, significantly reduces pain compared with placebo or rectal gel alone.¹³ Research also shows that injecting anesthetic at both the base and the apex of the prostate provides better pain control than the base alone, particularly during targeted biopsy.¹⁴ If your urologist does not mention anesthesia beyond rectal lidocaine gel, it is worth asking about a nerve block.

Blood in the semen is the most common aftereffect. A prospective study found that 90% of men who could ejaculate after a transrectal biopsy experienced blood-tinged semen, with a mean duration of about four weeks.¹⁵ Blood in urine and stool is also common, usually resolving within a few days. These are almost always harmless, but no one warns you how alarming they look the first time.

Erectile function can also take a temporary hit. A meta-analysis found that erectile function scores dropped by a meaningful amount at one month after biopsy, but returned to baseline by three months and remained normal at six months.¹⁶ One prospective study suggested a somewhat longer trajectory, with scores still somewhat reduced at three and six months, though the study had methodological quirks that the larger meta-analysis helps contextualize.¹⁷ Either way, the effect is temporary for most men.

Infection Risk and the Antibiotic Question

If you are having a transrectal biopsy, your doctor will prescribe prophylactic antibiotics. The standard for years was a fluoroquinolone like ciprofloxacin. But rising rates of drug-resistant rectal bacteria have made this one-size-fits-all approach less reliable. A systematic review of randomized trials found that tailoring the antibiotic choice to a rectal swab taken before the biopsy cut febrile urinary tract infection rates roughly in half compared with giving everyone the same empiric drug.¹⁸ A prospective comparative study found the difference even more sharply: febrile infections occurred in about 8.5% of patients receiving empiric prophylaxis but in zero patients receiving swab-guided antibiotics.¹⁹

The simplest way to sidestep this issue entirely is the transperineal route, which avoids the rectum and its bacterial flora. For centers still performing transrectal biopsies, asking about rectal-swab-guided prophylaxis is a reasonable conversation to have.

Newer Tools on the Horizon

Several technologies are reshaping how prostate biopsy decisions get made and how the procedure itself is guided.

Blood-based biomarker panels like the 4Kscore and the Prostate Health Index go beyond plain PSA by measuring multiple related proteins. These tests provide a personalized risk percentage for high-grade cancer, helping men with borderline PSA levels decide whether a biopsy is truly warranted.²⁰ A review of screening strategies confirmed that these novel biomarker models are generally better than PSA alone at detecting clinically significant cancer while reducing unnecessary biopsies.²¹

Micro-ultrasound, operating at 29 MHz compared with the 6-to-9 MHz of conventional ultrasound, produces much higher resolution images in real time. Level 1 evidence now shows that micro-ultrasound is non-inferior to MRI for detecting clinically significant cancer in men who have not been previously biopsied.²² A head-to-head trial found micro-ultrasound-targeted biopsy detected 97% of the significant cancers that MRI-targeted biopsy found.²³ The potential advantage is that micro-ultrasound can be done in the procedure room during the biopsy itself, without requiring a separate MRI appointment. A larger three-arm randomized trial is underway to further clarify where micro-ultrasound fits.²⁴

PSMA PET scans, already well established for staging advanced prostate cancer, are being explored for primary diagnosis. In one study of men who had negative standard biopsies but a PSMA-avid lesion on imaging, PSMA PET-guided targeted biopsy diagnosed cancer in 39 out of 43 cases, many of which were in the anterior prostate where standard approaches struggle.²⁵ A prospective randomized study also found that PSMA PET/CT could serve as a triage tool and improve detection of significant cancer, particularly in the mid-range PSA zone.²⁶ PSMA PET is not yet standard before a first biopsy, but it is increasingly used when previous biopsies have been negative yet suspicion remains.

The Psychological Weight of the Procedure

The physical side effects get most of the attention, but the psychological toll is real and underappreciated. About half of men who undergo prostate biopsy report significant procedure-related distress, with higher rates among those who receive a cancer diagnosis or an inconclusive result.²⁷ Even a negative biopsy result does not erase the anxiety quickly. One study found that about 20% of men reported high distress around the time of biopsy, and those distress levels remained meaningfully elevated even 12 weeks after receiving a clean result.²⁸ Among men with a positive result, anxiety scores rose significantly, particularly when PSA levels were very high.²⁹

A Korean multicenter study looking at decision regret found that overall regret rates after biopsy were low, at about 5%. But regret spiked dramatically among men who felt they had received an insufficient explanation of the PSA test and its implications before the procedure, and among men with lower media literacy or weaker social support networks.³⁰ The takeaway is simple: feeling informed and supported before the biopsy matters as much for emotional outcomes as the physical preparation does.

Needle Tract Seeding Is Extremely Rare

One fear that circulates online is that the biopsy needle could spread cancer cells along its path. A literature review identified only 42 reported cases of needle-tract seeding across all published prostate biopsy studies, putting the incidence well below 1%.³¹ Most reported cases involved large, locally advanced tumors, not the smaller, early-stage cancers that biopsies typically encounter today. An older series found perineal seeding in about 1% of cases, but almost exclusively in men with bulky disease.³² Despite the increase in both the number of biopsies performed and the number of cores taken per biopsy over the years, reported seeding cases have not increased. This is not a rational reason to refuse a biopsy.

The Repeat Biopsy Problem in Active Surveillance

Men with low-grade prostate cancer who choose active surveillance rather than immediate treatment face the prospect of repeated biopsies to check whether the cancer has changed. This creates a practical problem: side effects from one biopsy can make men reluctant to return for the next one. In the large international PRIAS active surveillance study, one in five men reported some form of complication after biopsy, and men who experienced a complication were significantly more likely to skip their next scheduled biopsy, at a rate of 21% versus 12% for those without complications.³³

A Japanese arm of the same study zeroed in on which complications drove avoidance. Pain was the strongest predictor of refusing a repeat biopsy, nearly five times more likely to cause refusal than having no complications at all. Blood in the urine also played a role, while infection and blood in the semen did not significantly predict avoidance.³⁴ This underscores why pain management during the initial biopsy is not just a comfort issue but a clinical one: inadequate pain control can compromise a man’s entire surveillance trajectory.

Who Gets the Best Biopsy

Not everyone has equal access to the most advanced biopsy techniques. Pre-biopsy MRI use in the United States has shown persistent racial and socioeconomic disparities. A population-based study found that non-Hispanic Black men were significantly less likely to receive a pre-biopsy prostate MRI than non-Hispanic White men, with non-Hispanic Black men having about 72% lower odds of MRI use. Men in less urban areas also had lower rates.³⁵ A larger analysis tracking trends over time found that this gap narrowed somewhat between 2012 and 2019, with the relative disparity shrinking from about 43% to 20%, but it did not disappear. Income, education level, and insurance status all remained associated with who got MRI and who did not.³⁶

A systematic review and meta-analysis across over 94,000 cases confirmed the pattern at a broad level: White and Caucasian patients accounted for roughly two-thirds of MRI utilization, while Black patients accounted for about 19% and Hispanic patients around 7%.³⁷ These gaps matter because MRI-guided biopsy is better at catching significant cancers and avoiding unnecessary procedures. Men who do not receive MRI are more likely to undergo blind systematic biopsies, with all the attendant limitations in accuracy. Given that Black men have both higher prostate cancer incidence and higher mortality, the irony of lower access to the best diagnostic tools is difficult to overstate.